Effect Profile
CuratedStrong euphoria and pain relief with moderate itching/nausea and sedation
Tolerance & Pharmacokinetics
drugs.wikiCross-Tolerances
Harm Reduction
drugs.wikiRarely sold in pure form; most user encounters arise from black-tar heroin or deliberate synthesis. Potency ≈30 % higher than heroin by weight. Extremely short plasma half-life produces a sharp rush but also a steep post-peak crash. Naloxone fully reverses effects. Ethanol slows 6-MAM → morphine conversion, compounding respiratory depression. Modern drug checking programmes repeatedly find high variability in heroin potency, occasional inclusion of other high-potency opioids, benzodiazepine-type drugs, and veterinary tranquilizers (e.g., xylazine); start with a very small dose, avoid polydrug use, and check samples where possible. Fentanyl/‘benzo-dope’/‘tranq-dope’ mixtures raise overdose risk and may require repeated naloxone while providing only partial benefit if non-opioids are present; continue rescue breaths and call emergency services immediately. Naloxone acts within minutes but typically lasts ~20–40 min—renarcotization can occur as morphine levels or other opioids outlast naloxone, so monitor continuously and re-dose if breathing slows. After any abstinence (detox, jail, illness), tolerance drops quickly and overdose risk is markedly higher on prior ‘usual’ doses—halve or more if returning to use, and ideally use with someone who can intervene. For injection: use sterile water, correct acidifiers only when needed (citric/ascorbic for base forms), and avoid vinegar/lemon to reduce infection risk; use clean equipment every time and seek local needle/syringe services for supplies and wound care. For smoking: use foil, test tiny amounts first, and avoid deep sedation alone. Fentanyl test strips can be useful where permitted, but follow instructions carefully—the method and dilution determine reliability.
References
Drugs.wiki References
- PubChem: 6-Acetylmorphine (compound record and synonyms)
- Rook et al., 2006: Population pharmacokinetics of heroin and its major metabolites (heroin and 6-MAM t½; inhalation bioavailability)
- EMCDDA/EUDA drug profile: Heroin (background on heroin→6-MAM→morphine metabolism; rapid CNS entry; overdose context)
- EMCDDA/EUDA European Drug Report – Harm reduction 2024 (benzo-/tranq-dope mixtures; preparedness for potent synthetics)
- EMCDDA/EUDA European Drug Report 2025 – Heroin and other opioids (polysubstance use with opioids → overdose risk)
- EMCDDA/EUDA: Misuse of benzodiazepines among high-risk opioid users (respiratory depression risk in combinations)
- Saferparty (Zurich, Bern) drug-checking warnings – high potency heroin; presence of 6-MAM as minor component; mis-sold heroin
- Saferparty: Heroin sold as cocaine – mislabelled products increase overdose risk when insufflated
- Drug Checking Community: Toronto Drug Checking Service periodic reports (multiple high-potency opioids, benzos, and xylazine in opioid supply)
- DrugWise: Naloxone (onset minutes; duration ~20–40 min; need to re-dose and call EMS)
- DrugWise: Overdose – what to do (recognition and response)
- DrugWise: Harm reduction for drug users (safer injecting supplies, needle exchange, and BBV testing)
- DrugWise: Heroin and other opiates (post-detox loss of tolerance → overdose risk)
- DrugWise: Xylazine (sedation not reversed by naloxone; ulceration risk if injected)
- TripSit: Test Kits (importance of correct fentanyl test strip usage)
- DrugBank review: Buprenorphine can block opioids or precipitate withdrawal in dependent users
- Bluelight thread: Pure 6-MAM experiences (rare availability; user risk discussion)